Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial

American Heart Journal · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles